Abstract

The present disclosure provides a composition for nasal administration that is for inducing cellular immunity against viruses, the composition containing (i) a virus-derived antigen and (ii) a carboxyvinyl polymer.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/29 - Hepatitis virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants

Abstract

The present disclosure provides a vaccine adjuvant agent comprising a polymer in which a constitutional unit is derived from acrylic acid, wherein the polymer has a carboxyl group content of 60.0 to 62.5% by mass.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a formulation base prepared by adding polyethylene glycol to crosslinked polyacrylic acid, and a formulation for spraying nasal vaccine comprising an antigen, which have optimized spray pattern targeting simultaneously both of nasal mucosa and nasopharynx.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/29 - Hepatitis virus

Abstract

The present disclosure provides a vaccine adjuvant composition containing: a macromolecular polymer having acrylic acid as a constituent unit; and a cationic surfactant.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants

Abstract

A nasal spray/injection nozzle according to one embodiment of the present invention comprises a pair of sub-nozzles. Each of the sub-nozzles has an ejection hole formed at the leading end. The sub-nozzles are coupled to each other through a joining section. The separation distance between the axis of one of the sub-nozzles and the axis of the other sub-nozzle increases from the joining section toward the respective leading ends.

IPC Classes  ?

• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 15/08 - Inhaling devices inserted into the nose

Abstract

Provided is a nasal delivery device capable of easily delivering a medicinal solution. A nasal delivery device that delivers a medicinal solution from a vial enclosing the medicinal solution, the device comprising a nozzle portion that jets the medicinal solution, a syringe connected to the nozzle portion and having a substantially hollow cylindrical shape, a plunger disposed in an insertable manner in an axial direction between an initial position and a push-in position with respect to the syringe, the plunger including a main body having a substantially columnar shape, a gasket disposed at one end of the main body, and a disk portion that applies a pressing force, the disk portion being disposed at the other end of the main body, and a restoring elastic portion that deforms and generates a restoring force as the plunger moves from the initial position to the push-in position with respect to the syringe, wherein an inner wall of the syringe and the gasket of the plunger define a first space that holds the medicinal solution in the nasal delivery device, and the medicinal solution is delivered to the first space as the restoring elastic portion is restored to an original shape by the restoring force.

IPC Classes  ?

• A61M 3/02 - EnemataIrrigators

Abstract

The present invention addresses the problem of providing a vaccine composition for nasal administration that is usable for preventing and treating hepatitis B, and a nasal administration system of the vaccine.　Provided is a hepatitis B vaccine composition that comprises: (i) virus-like particles containing hepatitis B surface L antigen proteins (HBs-L antigen proteins) of two or more genotypes selected from the group consisting of types A, B, C and D, and a hepatitis B nucleocapsid antigen (HBc antigen) protein; and (ii) a base material containing a carboxyvinyl polymer having been treated by externally applying a shear force. Also provided is a nasal administration system of the hepatitis B vaccine, said system comprising the composition filled into a sprayable device equipped with a nasal spray nozzle.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 9/12 - AerosolsFoams
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 31/20 - Antivirals for DNA viruses
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
• C07K 19/00 - Hybrid peptides
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

The present disclosure provides a vaccine adjuvant agent which contains a high molecular weight polymer that comprises an acrylic acid as a constituent unit, while having a carboxyl group content of 60.0% by mass to 62.5% by mass.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 47/02 - Inorganic compounds
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention pertains to a formulation that for spraying a nasal vaccine, that contains an antigen and a base agent obtained by adding polyethylene glycol to a crosslinkable polyacrylic acid, and that has an optimized spray pattern for simultaneously targeting the nasal mucosa and the nasopharynx.

IPC Classes  ?

• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 9/08 - Solutions
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/09 - Streptococcus
• A61K 39/10 - BrucellaBordetella, e.g. Bordetella pertussis
• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/20 - Rubella virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/235 - Adenoviridae
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 39/25 - Varicella-zoster virus
• A61K 39/29 - Hepatitis virus
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

Provided is a method for producing trimeric and tetrameric IgA antibodies, the method including mixing dimeric IgA antibodies and monomeric IgA antibodies.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A nasal spray/injection nozzle according to one embodiment of the present invention comprises a pair of sub-nozzles. Each of the sub-nozzles has an ejection hole formed at the leading end. The sub-nozzles are coupled to each other through a joining section. The separation distance between the axis of one of the sub-nozzles and the axis of the other sub-nozzle increases from the joining section toward the respective leading ends.

IPC Classes  ?

• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

The present invention relates to a composition wherein olopatadine is stably dissolved and a process thereof.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present invention relates to a homogeneous composition comprising a steroid compound and olopatadine, wherein the steroid compound is in a stable suspension state, and the olopatadine is in a stable solution state, and a process thereof.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

There is provided a nasal spray/spout nozzle capable of further improving the performance of a medicament delivery with respect to a target site located in a nasal cavity. The nasal spray/spout nozzle comprises a tip portion having a nozzle exit port, and a nose rest capable of abutting on a nose region around an external naris.

IPC Classes  ?

• A61M 15/08 - Inhaling devices inserted into the nose
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

Provided is a method for producing trimeric and tetrameric IgA antibodies, the method including mixing dimeric IgA antibodies and monomeric IgA antibodies.

IPC Classes  ?

• C07K 1/00 - General processes for the preparation of peptides
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 38/06 - Tripeptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 1/14 - ExtractionSeparationPurification
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to a pharmaceutical composition comprising fluticasone furoate and carboxy vinyl polymer.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present invention relates to a rhinovaccination system for preventing and treating hepatitis B, comprising a hepatitis B vaccine composition for administration to nasal mucosa in combination with a medical nozzle device.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 9/12 - AerosolsFoams
• A61K 39/12 - Viral antigens
• A61K 39/29 - Hepatitis virus
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present invention pertains to: a composition in which olopatadine exists stably in a dissolved state; and a manufacturing method for the composition.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 9/08 - Solutions
• A61K 9/12 - AerosolsFoams
• A61K 47/02 - Inorganic compounds
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 27/02 - Ophthalmic agents
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to: a homogeneous composition which comprises a steroid compound and olopatadine and in which the steroid compound and olopatadine are present stably in a suspended state and in a dissolved state, respectively; and a method for producing the composition.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 9/10 - DispersionsEmulsions
• A61K 9/12 - AerosolsFoams
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a nasal spray injection nozzle capable of further improving drug delivery to a target site within a nasal cavity. This nasal spray injection nozzle has: a distal end portion having a nozzle injection hole; and a nose rest that can be brought into contact with a portion around a nostril.

IPC Classes  ?

• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 11/08 - Pocket atomisers of the injector type

Abstract

The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.

IPC Classes  ?

• A61P 31/20 - Antivirals for DNA viruses
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 39/29 - Hepatitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a transnasal administration system which can be used for the prevention and treatment of hepatitis B and is combined with a medical nozzle device for use in the administration of a hepatitis B vaccine composition to the nasal cavity mucosa, wherein the hepatitis B vaccine composition is intended to be administered with a trans-nasal-mucosa spray.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 9/06 - OintmentsBases therefor
• A61K 9/12 - AerosolsFoams
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to a pharmaceutical composition containing fluticasone furoate and a carboxyvinyl polymer.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/08 - Solutions
• A61K 9/12 - AerosolsFoams
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to a hepatitis B vaccine composition for nasal mucosa spraying administration, characterized by comprising a hepatitis B antigen and a gel base containing a carboxyl vinyl polymer, and by being applicable to hepatitis B prevention and treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/12 - AerosolsFoams
• A61K 39/29 - Hepatitis virus
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants